On January 18, 2022, the Pan-Canadian Formulary Advisory Panel will be presenting an information session with their recommendations for the development of a framework for a potential pan-Canadian prescription drug list, or formulary.
The Advisory Panel was established by the Canadian Agency for Drugs and Technologies in Health (CADTH) at the request of Health Canada. The information session will focus on the principles for developing a pan-Canadian formulary framework, a sample list of prescribed drugs to include on the potential formulary as a test case, and criteria and processes for expanding the sample list. Registration is free.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
PMPRB consults further on revised proposed practice directions
The Patented Medicine Prices Review Board (PMPRB) holds public hearings on two types of mattersRead More -
Health Canada takes action to address generic drug submission review backlog
Health Canada is not currently meeting its performance standards for the review of some generic drug submissions. On September 1, 2026, Health Canada launched a new webpage, Improving how we review ge...Read More -
PMPRB releases September 2026 NEWSletter
The September NEWSletter also provides information about the PMPRB’s participation in past and future events, as well as NPDUIS research initiative and activities.Read More
